Literature DB >> 1527541

Aluminium intoxication in undialysed adults with chronic renal failure.

L S Russo1, G Beale, S Sandroni, W E Ballinger.   

Abstract

The dialysis encephalopathy syndrome (DES) consists of altered mental status, communication difficulty, seizures and myoclonus. It has been attributed to elevated serum aluminium (A1) levels. Two undialysed patients with chronic renal failure who presented with the characteristic syndrome are reported. The first, a 48 year old female, had used A1 containing phosphate binders for two years. Her serum A1 level was 25.34 mumol/L. Despite treatment with desferoximine and dialysis, she died. Necropsy revealed elevated A1 levels in the cerebral cortex (19 mcg/gm) and spongioform change in the outer three cortical layers. The second patient, a 46 year old woman, had a serum A1 of 8.70 mumol/L. She had never taken A1 containing phosphate binders but had taken several grams/day of citrate for at least six months. Treatment with haemodialysis and discontinuation of the citrate produced a resolution of symptoms and return of the A1 level to normal. During two years of haemodialysis there has been no recurrence.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1527541      PMCID: PMC489208          DOI: 10.1136/jnnp.55.8.697

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  12 in total

1.  The dialysis encephalopathy syndrome. Possible aluminum intoxication.

Authors:  A C Alfrey; G R LeGendre; W D Kaehny
Journal:  N Engl J Med       Date:  1976-01-22       Impact factor: 91.245

2.  Acute fatal hyperaluminemic encephalopathy in undialyzed and recently dialyzed uremic patients.

Authors:  A A Bakir; D O Hryhorczuk; E Berman; G Dunea
Journal:  ASAIO Trans       Date:  1986 Jul-Sep

3.  Hyperaluminaemia from aluminum resins in renal failure.

Authors:  G M Berlyne; J Ben-Ari; D Pest; J Weinberger; M Stern; R Levine; G R Gilmore
Journal:  Lancet       Date:  1970-09-05       Impact factor: 79.321

4.  Gastrointestinal absorption of aluminum from aluminum-containing antacids.

Authors:  W D Kaehny; A P Hegg; A C Alfrey
Journal:  N Engl J Med       Date:  1977-06-16       Impact factor: 91.245

5.  Syndrome of dyspraxia and multifocal seizures associated with chronic hemodialysis.

Authors:  A C Alfrey; J M Mishell; J Burks; S R Contiguglia; H Rudolph; E Lewin; J H Holmes
Journal:  Trans Am Soc Artif Intern Organs       Date:  1972

6.  Aluminium, neurofibrillary degeneration and Alzheimer's disease.

Authors:  D R Crapper; S S Krishnan; S Quittkat
Journal:  Brain       Date:  1976-03       Impact factor: 13.501

7.  Evidence for aluminium accumulation in renal failure.

Authors:  S N Marsden; I S Parkinson; M K Ward; H A Ellis; D N Kerr
Journal:  Proc Eur Dial Transplant Assoc       Date:  1979

8.  Dialysis encephalopathy: neuropathologic aspects.

Authors:  M D Winkelman; E S Ricanati
Journal:  Hum Pathol       Date:  1986-08       Impact factor: 3.466

9.  Metabolism and toxicity of aluminum in renal failure.

Authors:  A C Alfrey; A Hegg; P Craswell
Journal:  Am J Clin Nutr       Date:  1980-07       Impact factor: 7.045

10.  Brain-aluminium concentration in dialysis encephalopathy.

Authors:  J R McDermott; A I Smith; M K Ward; I S Parkinson; D N Kerr
Journal:  Lancet       Date:  1978-04-29       Impact factor: 79.321

View more
  4 in total

Review 1.  The neurotoxicity of environmental aluminum is still an issue.

Authors:  Stephen C Bondy
Journal:  Neurotoxicology       Date:  2010-05-27       Impact factor: 4.294

2.  Dialysis-associated encephalopathy: light and electron microscopic morphology and topography with evidence of aluminum by laser microprobe mass analysis.

Authors:  E Reusche; U Seydel
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

3.  Widespread aluminium deposition in extracerebral organ systems of patients with dialysis-associated encephalopathy.

Authors:  E Reusche; B Lindner; H Arnholdt
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

Review 4.  Safety of new phosphate binders for chronic renal failure.

Authors:  Mahmoud Loghman-Adham
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.